Yazar "Deger, U." seçeneğine göre listele

Listeleniyor 1 - 2 / 2
  • [ X ]
    Öğe
    Effects of Potentilla fulgens on Tuba Uterina in Ovariectomized Rats
    (Soc Chilena Anatomia, 2016) Acar, Zuat; Deger, U.; Gorkem, U.; Togrul, Cihan; Deveci, E.; Kaya, S.; Ekinci, A.
    A total of 32 Wistar rats were divided into four equal groups: (I) sham, (II) ischemia, (III) reperfusion and (IV) Potentilla fulgens. In groups I and II, ovary torsion was not performed and no drug was administered. In group III, 1 h of ischemia and 2 h of reperfusion were performed and no drug was given. Group IV received 400 mg/kg/day Potentilla fulgens intraperitoneally 5 days before Ischemia-reperfusion. All the parameters were observed to be significantly decreased (P<0.05) in all the experimental groups compared to the control group. In the sections of the ischemia-reperfusion group, degeneration of epithelium, dilation of blood vessels were observed. Potentilla fulgens administration reduced the morphological changes by induced I/R; in particular, infiltration, hemorrhage and vascular dilatation were decreased. Potentilla fulgens application during torsion, it plays an important role in maintaining the epithelial structure with E-cadherin expression. We suggest that PECAM-1(CD31) are a regulator of the microvascular response of the tubal mucosa.
  • [ X ]
    Öğe
    The relationship between complete hydatidiform mole and serum Vitamin D level: a prospective case-control study
    (Verduci Publisher, 2022) Gunduz, R.; Deger, U.; Kaplan, I; Tepe, N. Bayramoglu; Tunc, S. Yaman; Icen, M. S.; Agacayak, E.
    OBJECTIVE: This study aimed to determine whether or not there was a relations-hip between complete hydatidiform mole (CHM) and serum Vitamin D level by comparing CHM patients with two control groups and to determi-ne whether or not Vitamin D deficiency is a risk factor for CHM. PATIENTS AND METHODS: This prospec-tive study included 30 patients diagnosed with CHM (case group), 30 patients in the first trimes-ter of a healthy pregnancy (control group), and 30 healthy non-pregnant subjects (control group). A record was made of serum 25-hydroxyvitamin D (25-OH D vitamin) levels, age, body mass index (BMI), gravida, parity, and the number of abortus. The serum 25-OH D vitamin levels were examined in each group and compared between groups. RESULTS: The 25-OH D vitamin level of all the patients in the study was determined as 11.16 +/- 8.64 ng/mL. No significant difference was determined between the groups in respect of 25 OH-D vitamin levels. When comparisons were made between the four subgroups according to the 25-OH-D level, no significant difference was determined between the CHM and control groups. When the patients were separated as obese and non-obese groups, no significant dif-ference was determined between the groups. CONCLUSIONS: Severe deficiency, deficien-cy, or insufficient levels of serum Vitamin D are not thought to be risk factors for CHM patients.